Advances in the Surgical Treatment of Urologic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 2449

Special Issue Editor


E-Mail Website
Guest Editor
Department of Urology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
Interests: bladder cancer; urachal cancer; urology; endourology; urologic oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In urological oncology, the four most prevalent tumors develop in the prostate, bladder, kidney and testicles. In the bladder, we can find non-muscle invasive tumors and muscle invasive tumors, requiring totally a different approach and type of surgery. In the kidney, both renal cell carcinomas and urothelial carcinomas can be found in the collecting system. Apart from (topical) chemo- and immunotherapy, surgery still plays an important role in the treatment and cure of patients with urological tumors. Surgery may range from endoscopic surgery for non-invasive bladder and pyelum tumors, to minimal invasive radical surgery by laparoscopy (e.q. smaller kidney tumors) or robotic surgery (e.g. invasive bladder tumors, prostate cancer and partial nephrectomies) to open radical surgery (e.g. in bladder cancer, residual masses after chemotherapy for testicular cancer, and larger renal tumors).

In this Special Issue, several endoscopic, minimally invasive and open radical types of operation in cases of patients with urological tumors will be presented and discussed.

You may choose our Joint Special Issue in Current Oncology.

Dr. Laura S. Mertens
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • prostate cancer
  • testicular cancer
  • kidney cancer
  • surgery
  • robotic
  • laparoscopy
  • transurethral resection

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 900 KiB  
Review
Sentinel Lymph Node Techniques in Urologic Oncology: Current Knowledge and Application
by Bartosz Małkiewicz, Paweł Kiełb, Maximilian Kobylański, Jakub Karwacki, Adrian Poterek, Wojciech Krajewski, Romuald Zdrojowy and Tomasz Szydełko
Cancers 2023, 15(9), 2495; https://doi.org/10.3390/cancers15092495 - 26 Apr 2023
Cited by 5 | Viewed by 2075
Abstract
Lymph node (LN) metastases have a significant negative impact on the prognosis of urological malignancies. Unfortunately, current imaging modalities are insufficient when it comes to detecting micrometastases; thus, surgical LN removal is commonly used. However, there is still no established ideal lymph node [...] Read more.
Lymph node (LN) metastases have a significant negative impact on the prognosis of urological malignancies. Unfortunately, current imaging modalities are insufficient when it comes to detecting micrometastases; thus, surgical LN removal is commonly used. However, there is still no established ideal lymph node dissection (LND) template, leading to unnecessary invasive staging and the possibility of missing LN metastases located outside the standard template. To address this issue, the sentinel lymph node (SLN) concept has been proposed. This technique involves identifying and removing the first group of draining LNs, which can accurately stage cancer. While successful in breast cancer and melanoma, the SLN technique in urologic oncology is still considered experimental due to high false-negative rates and lack of data in prostate, bladder, and kidney cancer. Nevertheless, the development of new tracers, imaging modalities, and surgical techniques may improve the potential of the SLN procedures in urological oncology. In this review, we aim to discuss the current knowledge and future contributions of the SLN procedure in the management of urological malignancies. Full article
(This article belongs to the Special Issue Advances in the Surgical Treatment of Urologic Cancer)
Show Figures

Figure 1

Back to TopTop